Author

A. Astudillo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

A. Agraz-Doblas· 1 shared A. Brana· 1 shared A. F. Fernandez· 1 shared A. Rodriguez· 1 shared B. Casar· 1 shared B. Gallego· 1 shared B. Monterde· 1 shared C. Huergo· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Agraz-Doblas

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma

V. Rey, J. Tornin, J. J. Alba-Linares, C. Robledo, D. Murillo, A. Rodriguez, B. Gallego, C. Huergo, A. Brana, A. Astudillo, D. Heymann, A. F. Fernandez, M. F. Fraga, J. Alonso, R. Rodriguez

This study identifies enasidenib as an effective treatment for IDH2 mutant chondrosarcoma through personalized medicine approaches involving sequencing, cell line models, and in vitro/in vivo testing.

eBioMedicine · Apr 1, 2024Peer-reviewedCancer Biology

ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to PARP inhibition in lung cancer

T. Moreno, L. Gonzalez-Silva, B. Monterde, I. Betancor-Fernandez, C. Revilla, A. Agraz-Doblas, J. Freire, P. Isidro, L. Quevedo, S. Montes-Moreno, L. Cereceda, A. Astudillo, B. Casar, P. Crespo, C. Morales Torres, , I. Varela

This study identifies ARID2 deficiency in 20% of lung cancer patients, showing it promotes tumor progression and increases sensitivity to PARP inhibition.

bioRxiv · Jan 10, 2020Cancer Biology